Citigroup
TVRD

Citigroup’s Tvardi Therapeutics TVRD Stock Holding History

Citigroup’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$878 Buy
276
+153
+124% +$599 ﹤0.01% 5495
2025
Q4 		$529 Buy
123
+51
+71% +$457 ﹤0.01% 5583
2025
Q3 		$2.81K Sell
72
-1,080
-94% -$30.8K ﹤0.01% 5405
2025
Q2 		$26.9K Buy
+1,152
New +$27.2K ﹤0.01% 5009
2025
Q1 		– Sell
-641
Closed -$11.8K – 6066
2024
Q4 		$11.8K Sell
641
-1
-0.2% -$11 ﹤0.01% 5353
2024
Q3 		$7.11K Sell
642
-178
-22% -$2.09K ﹤0.01% 5324
2024
Q2 		$7.62K Sell
820
-653
-44% -$15.6K ﹤0.01% 5203
2024
Q1 		$48.3K Buy
1,473
+67
+5% +$1.74K ﹤0.01% 4643
2023
Q4 		$37.6K Buy
1,406
+161
+13% +$6.67K ﹤0.01% 4667
2023
Q3 		$75.3K Sell
1,245
-392
-24% -$36.8K ﹤0.01% 4016
2023
Q2 		$167K Sell
1,637
-322
-16% -$44.4K ﹤0.01% 3980
2023
Q1 		$346K Sell
1,959
-99
-5% -$33.2K ﹤0.01% 3386
2022
Q4 		$796K Buy
2,058
+27
+1% +$10.3K ﹤0.01% 2831
2022
Q3 		$685K Sell
2,031
-160
-7% -$58K ﹤0.01% 3005
2022
Q2 		$720K Sell
2,191
-208
-9% -$73K ﹤0.01% 2942
2022
Q1 		$1.05M Buy
2,399
+129
+6% +$53K ﹤0.01% 2917
2021
Q4 		$995K Buy
2,270
+1,045
+85% +$525K ﹤0.01% 3269
2021
Q3 		$681K Buy
1,225
+304
+33% +$153K ﹤0.01% 3398
2021
Q2 		$473K Buy
921
+743
+417% +$471K ﹤0.01% 3750
2021
Q1 		$139K Sell
178
-228
-56% -$156K ﹤0.01% 4216
2020
Q4 		$221K Buy
406
+125
+44% +$65.5K ﹤0.01% 4915
2020
Q3 		$129K Sell
281
-257
-48% -$149K ﹤0.01% 4928
2020
Q2 		$331K Sell
538
-40
-7% -$22.1K ﹤0.01% 4619
2020
Q1 		$275K Sell
578
-131
-18% -$71.2K ﹤0.01% 4453
2019
Q4 		$411K Sell
709
-1,054
-60% -$740K ﹤0.01% 4598
2019
Q3 		$1.16M Sell
1,763
-1,733
-50% -$1.44M ﹤0.01% 3479
2019
Q2 		$2.71M Buy
3,496
+2,363
+209% +$1.66M ﹤0.01% 2525
2019
Q1 		$800K Sell
1,133
-7,159
-86% -$4.29M ﹤0.01% 3654
2018
Q4 		$3.88M Buy
8,292
+5,769
+229% +$3.72M ﹤0.01% 2056
2018
Q3 		$2.18M Buy
2,523
+2,113
+515% +$1.53M ﹤0.01% 2652
2018
Q2 		$283K Sell
410
-316
-44% -$161K ﹤0.01% 4694
2018
Q1 		$324K Buy
726
+347
+92% +$168K ﹤0.01% 4452
2017
Q4 		$167K Sell
379
-919
-71% -$419K ﹤0.01% 5205
2017
Q3 		$639K Buy
1,298
+508
+64% +$254K ﹤0.01% 3849
2017
Q2 		$438K Buy
790
+769
+3,662% +$488K ﹤0.01% 4109
2017
Q1 		$14K Buy
21
+7
+50% +$3.74K ﹤0.01% 6433
2016
Q4 		$5K Hold
14
– – ﹤0.01% 6940
2016
Q3 		$4K Sell
14
-38
-73% -$8.23K ﹤0.01% 6832
2016
Q2 		$9K Sell
52
-549
-91% -$120K ﹤0.01% 6607
2016
Q1 		$134K Buy
601
+331
+123% +$98.9K ﹤0.01% 5447
2015
Q4 		$164K Buy
270
+234
+650% +$128K ﹤0.01% 4924
2015
Q3 		$18K Sell
36
-51
-59% -$34.1K ﹤0.01% 6111
2015
Q2 		$38K Sell
87
-1,456
-94% -$563K ﹤0.01% 5719
2015
Q1 		$558K Buy
1,543
+33
+2% +$12.5K ﹤0.01% 3637
2014
Q4 		$542K Buy
1,510
+1,505
+30,100% +$485K ﹤0.01% 3804
2014
Q3 		$2K Buy
5
+3
+150% +$1.23K ﹤0.01% 6825
2014
Q2 		$1K Buy
+2
New +$1.08K ﹤0.01% 6967

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Citigroup's TVRD Position: Q1 2026 in Review

Citigroup increased its Tvardi Therapeutics (TVRD) stake by 124% in Q1 2026, buying an estimated $599 and bringing the position to 276 shares worth $878. The position accounts for ﹤0.01% of the portfolio, ranked #5495.

Citigroup first reported a position in TVRD in Q2 2014 and has held it in 47 quarters since. The position peaked at $3.88M in Q4 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Citigroup held 276 shares of Tvardi Therapeutics worth $878 as of Q1 2026.
  • Citigroup bought 153 Tvardi Therapeutics shares in Q1 2026, an estimated $599.
  • Tvardi Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5495 holding.
  • Citigroup first reported a position in Tvardi Therapeutics in Q2 2014 and has held it in 47 quarters since.
  • Citigroup's Tvardi Therapeutics position peaked at $3.88M in Q4 2018.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.